

Figure 3 Patient No 1. Fibre-tracking of the pyramidal tracts was disrupted in a 67-year-old man with a left fronto-parietal glioblastoma multiforme. Upper: preoperative T2 weighted MRI identified a focus of hyperintensity in the left perirolandic region with gadolinium enhancement of the rostral precentral cortex. Stimulation of the left cortex rarely elicited weak motor evoked potential (MEP) responses on the right abductor pollicis brevis muscle. Subcortical stimuli, even on the approximated posterior bank of the precentral gyrus on neuronavigation (intersection of the yellow lines in the intraoperative navigation image), did not elicit MEPs. Middle: a relative anisotropy map indicated the principal eigenvector (green, anterior–posterior; red, right–left; and blue, inferior–superior). Fibre-tracking of the left pyramidal tracts (red lines) near the tumour was disrupted during its course to the cortex. Lower: postoperative MRI with gadolinium enhancement.

current. During removal of tumour tissue within 2 cm of the pyramidal tracts by intraoperative neuronavigation, we performed repetitive subcortical electrical stimulations. Electrical stimuli were applied across a relatively wide area to avoid any anatomical shift caused by the tumour. Five trains of monophasic square waves with a duration of 0.2 ms were applied. Current was delivered by a pair of adjacent electrodes (3 mm in diameter) with a centre-to-centre inter-electrode distance of 1 cm.[3] A 50 Hz electric current was delivered for language and sensory testing. Language functions were assessed by the reading of a paragraph, spontaneous speech, naming and comprehension activities.[17] We confirmed the points of stimulation by visualisation using the navigation system. In all patients, the minimum distances between points of stimulation and the fibre-tracking pyramidal tracts were measured using three dimensional MRI by intraoperative neuronavigation.

Surgery

All patients underwent removal of their tumour under local anaesthesia using the combination of tractography integrated functional neuronavigation and direct cortical/subcortical stimulation. During removal of the tumours around the pyramidal tracts, motor function of all four extremities was continuously monitored using the muscle manoeuvre test.[18] Language function was evaluated using similar testing as that used for electrical stimulation, depending on the location of the tumour. In three patients in whom part of the tumour extended into the left angular gyrus, single digit multiplication was evaluated. All procedures were approved by the ethics committee (No 542); written informed consent was obtained from all patients. As the presence of subcortical MEPs during resection of the tumour is an important sign warning of permanent motor weakness, we avoided further resection after obtaining the first MEP response.[19 20]

RESULTS

Results of evaluation of motor function by preoperative and intraoperative assessments are summarised in table 2. Preoperative fibre-tracking identified the pyramidal tracts of eight patients, including seven with mild hand motor weakness (patient Nos 4–10) and one with moderate motor weakness (3/5) of his upper limb (patient No 3) (figs 1, 2). In all patients, MEPs were elicited for all of the muscles evaluated, including the weakened muscles, by electrical stimulation of both the precentral gyrus and the subcortex within 1 cm of the pyramidal tracts, identified by intraoperative functional neuronavigation. The tumours were removed while confirming stable MEP responses by repetitive electrical stimulation. Motor function was either



Figure 4 Patient No 2. Left: fibre-tracking of the pyramidal tracts (red lines) demonstrated disruption around a left fronto-insulo-temporo-parietal glioblastoma multiforme. Middle: during removal of the tumour, cortical stimuli did not elicit any motor evoked potentials (MEPs). Subcortical stimuli very close to the predicted pyramidal tracts (red) on neuronavigation (intersection of the yellow lines in an intraoperative navigation image), however, elicited MEPs of her affected right lower extremities, but not her right upper extremities. Right: Postoperative T2 weighted MRI demonstrated that the pyramidal tracts identified by fibre-tracking (red) were preserved.

maintained or improved both during and after the operation. In addition, we demonstrated preservation of the pyramidal tracts by postoperative fibre-tracking (patient Nos 3, 4, 6 and 9).

In two patients (patient Nos 1 and 2), fibre-tracking of the pyramidal tracts around the tumour failed. Patient No 1 (fig 3) suffered from preoperative right hemiparesis (3/5 on the brachium, 4/5 on the hand and 2/5 on the leg) because of left fronto-parietal glioblastoma multiforme. Cortical SEPs exhibited weak responses on stimulation of the right median nerve; no response was observed after stimulation of the right tibial and sural nerves. Cortical stimulation of the anatomically confirmed precentral gyrus by neuronavigation elicited a rare MEP in his abductor pollicis brevis muscle; no MEPs were elicited in his biceps brachialis, deltoid, gastrocnemius, quadriceps femoris or tibialis anterior muscles. Neurological examinations soon after the patient recovered from general anaesthesia demonstrated no additional deficits. As the tumour was removed piece by piece, continuous evaluation of muscle strength helped preserve motor function of the lower extremities and improve motor function of the upper extremities to 4/5. Subcortical electrical stimulation did not elicit MEPs at any point during resection of the tumour. Patient No 2 (fig 4) exhibited right hemiparesis (1/5 on the upper extremity and 4/5 on the leg) preoperatively, caused by a left fronto-insulo-temporo-parietal glioblastoma multiforme. We operated on this patient with the goal of preserving motor function of the lower extremities. She also displayed mild motor aphasia. Cortical SEPs could not be elicited. Despite the absence of MEP responses following cortical stimulation of the wide area surrounding the anatomically identified precentral gyrus by neuronavigation, subcortical stimulation elicited MEPs of her lower but not upper extremities. Through continuous evaluation of muscle strength intraoperatively, motor function of the lower extremities was preserved during removal of the tumour. Postoperatively, she exhibited adequate removal of the tumour without any further neurological deficits.

DISCUSSION

To maintain the quality of life of patients with motor weakness undergoing surgical treatment of brain tumours, it is essential to evaluate motor function intraoperatively. The damage done to the pyramidal tracts, however, may affect the results of the evaluation. As MEPs elicited by direct intraoperative electrical stimulation remain the most reliable index of motor function,[21–23] it is important to predict if MEP responses will be elicited from the affected motor cortex and the pyramidal tracts during removal of the tumour. Presurgical evaluations, such as the degree of motor weakness (muscle strength), MEG, fMRI, positron emission tomography, transcranial magnetic stimulation and fibre-tracking are all potential candidates for predicting intraoperative MEP responses.

In this study, the degree of preoperative motor weakness did not always correlate with the incidence of intraoperative MEP responses. Muscles that were moderately affected by compression caused by the tumour elicited MEPs following cortical/subcortical stimulation (patient No 3), a result that is consistent with previous case reports.[2 24] MEP responses, however, could not be elicited from only mildly affected muscles in two patients (patient Nos 1 and 2). MEG, fMRI and positron emission tomography images provide information concerning motor function at the cortical, but not subcortical, level. Repetitive voluntary movements are often necessary to elicit motor evoked fields by MEG and bold effects by fMRI. While preoperative scalp SEPs correlated with the incidence of MEP responses in our patients, the results of SEP assessments do not directly reflect motor function.

Fibre-tracking of the affected pyramidal tracts was first compared with the incidence of intraoperative MEP responses by direct cortical/subcortical electrical stimulation. Subcortical MEPs were always elicited in regions in close proximity to the pyramidal tracts that had been predicted by fibre-tracking in patients with mild to moderate preoperative motor weakness. In addition, continuous fibre-tracking of the pyramidal tracts from the motor cortex to the cerebral peduncle indicated the positive response of cortical MEPs. On the other hand, cortical MEPs were never elicited as reliable responses in patients with disrupted fibre-tracking pyramidal tracts. These data suggest that preoperative fibre-tracking of the pyramidal tracts provides anatomical information as well as functional information in predicting the clinical usefulness of intraoperative cortical/subcortical electrical stimulation.

Several limitations to fibre-tracking as a preoperative evaluation, however, should be mentioned. Selection of the seed ROIs and the thresholding of fractional anisotropy, which define the parameter of the algorithm used in the procedure, may subjectively affect the errors in track trajectories.[8 25 26] In the present study, individual muscle maintained various degrees of motor activity preoperatively instead of disruption on the fibre-tracking pyramidal tracts, which may reflect the limitations of fibre-tracking from technical errors and pathological conditions. Part of the pyramidal fibres tracking from the precentral gyrus in lower convexity may fail to trace the precise course because the pyramidal tract intersects with callosal fibres and the superior longitudinal fasciculus at the level of the centrum semiovale.[3 27 28] Lack of visualisation of some upper limb fibres would account for some of the discrepancies between extent of weakness and ability to visualise fibres. To compare the pyramidal fibres tracking and MEP responses more precisely, taking intraoperative brain shift[29]

into consideration, DTI image processing during the course of surgery with the use of intraoperative MRI is needed.[3 30 31] In addition, individual pathophysiological factors resulting from the brain tumours may affect the results of fibre-tracking,[2 10 20 32 33] although it is controversial whether the tumour itself or peritumoral oedema on the pyramidal tracts can be distinguished by DTI metrics.[34 35] In the two such patients evaluated in this study, preservation of motor function indicated that secondary effects, such as oedema or mass effect, rather than tumour infiltration, caused the motor deficits. Relatively large amounts of peritumoral oedema in these patients compared with the other eight patients might cause unsuccessful fibre-tracking of the pyramidal tracts. Although a wide area was stimulated electrically, a portion of the pyramidal tracts may have been shifted by compression of the tumour. Further studies with a larger number of patients will be necessary to study the physiological significance of fibre-tracking of affected pyramidal tracts and to clarify the clinical relationship between preoperative fibre-tracking and intraoperative cortical/subcortical electrical stimulation. The tendency for patients not to be operated on until they begin to suffer from moderate motor weakness due to growing brain tumours may, however, limit these studies. In addition, post-operative fibre-tracking of the pyramidal tracts and neurological status should be compared with the extent of tumour resection for further verification of the clinical value of preoperative fibre-tracking.

Despite the clinical utility of complete pyramidal tract fibre-tracking in reliable MEPs of the motor cortex and pyramidal tracts, disruption of estimated pyramidal tracts suggested that electrical stimulation is insufficient to permit the preservation of motor function during tumour removal. For patients with mild to moderate motor weakness in whom pyramidal tract fibre-tracking failed preoperatively, awake surgery would be better suited to evaluate motor function by voluntary movement during removal of the tumour. As awake surgery allows spontaneous movements to be easily monitored continuously, it would be useful for a subset of pathological conditions.[36] During removal of a tumour under local anaesthesia, injuries to motor associated areas must also be considered. Motor weakness is not observed immediately after resection of the supplementary motor area[37] whereas an injury to the negative motor area after resection would cause an immediate and transient disturbance in fine movement.[17]

Authors' affiliations
Nobuhiro Mikuni, Rei Enatsu, Jun A Takahashi, Kazuhiko Nozaki, Nobuo Hashimoto, Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
Tsutomu Okada, Yukio Miki, Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
Shin-ichi Urayama, Hidenao Fukuyama, Human Brain Research Centre, Kyoto University Graduate School of Medicine, Kyoto, Japan

Competing interests: None.

REFERENCES

1 **Coenen VA**, Krings T, Axer H, *et al*. Intraoperative three-dimensional visualization of the pyramidal tract in a neuronavigation system (PTV) reliably predicts true position of principal motor pathways. *Surg Neurol* 2003;**60**:381–90.
2 **Kamada K**, Todo T, Masutani Y, *et al*. Combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. *J Neurosurg* 2005;**102**:664–72.
3 **Mikuni N**, Oakada T, Nishida N, *et al*. Comparison between motor evoked potential and fiber tracking for estimating pyramidal tracts near brain tumors. *J Neurosurg* 2007;**106**:128–33.
4 **Nimsky C**, Ganslandt O, Fahlbusch R. Implementation of fiber tract navigation. *Neurosurgery* 2006;**58**:292–304.
5 **Nimsky C**, Ganslandt O, Buchfelder M, *et al*. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. *Neurol Res* 2006;**28**:482–7.
6 **Okada T**, Mikuni N, Miki et al. Corticaspinal tract localization: integration of diffusion-tensor tractography at 3-T MR imaging with intraoperative white matter stimulation mapping—preliminary results. *Radiology* 2006;**240**:849–57.
7 **Hendler T**, Pianka P, Sigal M, *et al*. Delineating gray and white matter involvement in brain lesions: three-dimensional alignment of functional magnetic resonance and diffusion-tensor imaging. *J Neurosurg* 2003;**99**:1018–27.
8 **Mori S**, Crain BJ, Chacko VP, *et al*. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. *Ann Neurol* 1999;**45**:265–9.
9 **Wakana S**, Jiang H, Nagae-Poetscher LM, *et al*. Fiber tract-based atlas of human white matter anatomy. *Radiology* 2004;**230**:77–87.
10 **Witwer BP**, Moftakhar R, Hasan KM, *et al*. Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. *J Neurosurg* 2002;**97**:568–75.
11 **Yagishita A**, Nakano I, Oda M, *et al*. Location of the corticospinal tract in the internal capsule at MR imaging. *Radiology* 1994;**191**:455–60.
12 **Lee JS**, Han MK, Kim SH, *et al*. Fiber tracking by diffusion tensor imaging in corticospinal tract stroke: Topographical correlation with clinical symptoms. *Neuroimage* 2005;**26**:771–6.
13 **Okada T**, Miki Y, Fushimi Y, *et al*. Diffusion-tensor fiber tractography: intraindividual comparison of 3.0-T and 1.5-T MR imaging. *Radiology* 2006;**238**:668–78.
14 **Jiang H**, van Zijl PC, Kim J, *et al*. DtiStudio: resource program for diffusion tensor computation and fiber bundle tracking. *Comput Methods Programs Biomed* 2006;**81**:106–16.
15 **Naganawa S**, Koshikawa T, Kawai H, *et al*. Optimization of diffusion-tensor MR imaging data acquisition parameters for brain fiber tracking using parallel imaging at 3 T. *Eur Radiol* 2004;**14**:234–8.
16 **Yamada K**, Kizu O, Mori S, *et al*. Brain fiber tracking with clinically feasible diffusion-tensor MR imaging: initial experience. *Radiology* 2003;**227**:295–301.
17 **Mikuni N**, Ohara S, Ikeda A, *et al*. Evidence for a wide distribution of negative motor areas in the perirolandic cortex. *Clin Neurophysiol* 2006;**117**:33–40.
18 **Dejong RN**. Case taking and the neurological examination. In: Barker AB, eds. *Clinical neurology*. New York: Haeber-Harper, 1955:1–100.
19 **Keles GE**, Lundin DA, Lamborn KR, *et al*. Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. *J Neurosurg* 2004;**100**:369–75.
20 **Kinoshita M**, Yamada K, Hashimoto N, *et al*. Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition: initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. *Neuroimage* 2005;**25**:424–9.
21 **Duffau H**. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. *Lancet Neurol* 2005;**4**:476–86.
22 **Kombos T**, Suess O, Ciklatekerlio O, *et al*. Monitoring of intraoperative motor evoked potentials to increase the safety of surgery in and around the motor cortex. *J Neurosurg* 2001;**95**:608–14.
23 **Neuloh G**, Pechstein U, Cedzich C, *et al*. Motor evoked potential monitoring with supratentorial surgery. *Neurosurgery* 2004;**54**:1061–72.
24 **Duffau H**. Recovery from complete hemiplegia following resection of a retrocentral metastasis: the prognostic value of intraoperative cortical stimulation. *J Neurosurg* 2001;**95**:1050–2.
25 **Clark CA**, Barrick TR, Murphy MM, *et al*. White matter fiber tracking in patients with space-occupying lesions of the brain: a new technique for neurosurgical planning? *Neuroimage* 2003;**20**:1601–8.
26 **Lin CP**, Tseng WY, Cheng HC, *et al*. Validation of diffusion tensor magnetic resonance axonal fiber imaging with registered manganese-enhanced optic tracts. *Neuroimage* 2001;**14**:1035–47.
27 **Berman JI**, Berger MS, Mukherjee P, *et al*. Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. *J Neurosurg* 2004;**101**:66–72.
28 **Wiegell MR**, Larsson HB, Wedeen VJ. Fiber crossing in human brain depicted with diffusion tensor MR imaging. *Radiology* 2000;**217**:897–903.
29 **Reinges MH**, Nguyen HH, Krings T, *et al*. Course of brain shift during microsurgical resection of supratentorial cerebral lesions: limits of conventional neuronavigation. *Acta Neurochir (Wien)* 2004;**146**:369–77.
30 **Nimsky C**, Ganslandt O, Hastreiter P, *et al*. Intraoperative diffusion-tensor MR imaging: shifting of white matter tracts during neurosurgical procedures—initial experience. *Radiology* 2005;**234**:218–25.
31 **Nimsky C**, Ganslandt O, Hastreiter P, *et al*. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. *Neurosurgery* 2005;**56**:130–8.
32 **Beppu T**, Inoue T, Kuzu Y, *et al*. Utility of three-dimensional anisotropy contrast magnetic resonance axonography for determining condition of the pyramidal tract in glioblastoma patients with hemiparesis. *J Neurooncol* 2005;**73**:137–44.
33 **Laundre BJ**, Jellison BJ, Badie B, *et al*. Diffusion tensor imaging of the corticospinal tract before and after mass resection as correlated with clinical motor findings: preliminary data. *AJNR Am J Neuroradiol* 2005;**26**:791–6.
34 **Lu S**, Ahn D, Johnson G, *et al*. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. *Radiology* 2004;**232**:221–8.
35 **Provenzale JM**, McGraw P, Mhatre P, *et al*. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. *Radiology* 2000;**232**:451–60.
36 **Mikuni N**, Ikeda A, Yoneko H, *et al*. Surgical resection of an epileptogenic cortical dysplasia in the deep foot sensorimotor area: a case report. *Epilepsy Behav* 2005;**7**:559–62.
37 **Duffau H**, Lopes M, Denvil D, *et al*. Delayed onset of the supplementary motor area syndrome after surgical resection of the mesial frontal lobe: a time course study using intraoperative mapping in an awake patient. *Stereotact Funct Neurosurg* 2001;**76**:74–82.

J Neurosurg 106:593–598, 2007

Clinical impact of integrated functional neuronavigation and subcortical electrical stimulation to preserve motor function during resection of brain tumors

NOBUHIRO MIKUNI, M.D., PH.D.,[1] TSUTOMU OKADA, M.D.,[2] REI ENATSU, M.D.,[1] YUKIO MIKI, M.D., PH.D.,[2] TAKASHI HANAKAWA, M.D., PH.D.,[3] SHIN-ICHI URAYAMA, PH.D.,[3] KENICHIRO KIKUTA, M.D., PH.D.,[1] JUN A. TAKAHASHI, M.D., PH.D.,[1] KAZUHIKO NOZAKI, M.D., PH.D.,[1] HIDENAO FUKUYAMA, M.D., PH.D.,[3] AND NOBUO HASHIMOTO, M.D., PH.D.[1]

[1]Department of Neurosurgery, [2]Diagnostic Imaging and Nuclear Medicine, and [3]Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan

Object. The authors evaluated the clinical impact of combining functional neuronavigation with subcortical electrical stimulation to preserve motor function following the removal of brain tumors.

Methods. Forty patients underwent surgery for treatment of brain tumors located near pyramidal tracts that had been identified by fiber tracking. The distances between the electrically stimulated white matter and the pyramidal tracts were measured intraoperatively with tractography-integrated functional neuronavigation, and correlated with subcortical motor evoked potentials (MEPs) and clinical symptoms during and after resection of the tumors.

Motor function was preserved after appropriate tumor resection in all cases. In 18 of 20 patients, MEPs were elicited from the subcortex within 1 cm of the pyramidal tracts as measured using intraoperative neuronavigation. During resection, improvement of motor weakness was observed in two patients, whereas transient mild motor weakness occurred in two other patients. In 20 patients, the distances between the stimulated subcortex and the estimated pyramidal tracts were more than 1 cm, and MEPs were detected in only three of these patients following stimulation.

Conclusions. Intraoperative functional neuronavigation and subcortical electrical stimulation are complementary techniques that may facilitate the preservation of pyramidal tracts around 1 cm of resected tumors.

KEY WORDS • pyramidal tract • fiber tracking • motor evoked potential • motor function • neuronavigation

PRESERVING motor function while maximizing brain tumor resection is a major goal of neurosurgery. Presurgical noninvasive functional imaging, including positron emission tomography, functional MR imaging, and magnetoencephalography, enables the visualization of cortical areas involved in motor function, and has been integrated into functional neuronavigation. Cortical and subcortical functional connectivity can be clarified using intraoperative electrical stimulation.[9] To define the subcortical fibers from the primary motor cortex (the pyramidal tracts) as well as to monitor their motor function, MEPs elicited by direct electrical stimulation remain the most reliable index. Despite the use of presurgical cortical functional mapping and evaluation of MEPs, 7 to 20% of patients with perirolandic tumors suffer permanent motor weakness postoperatively, mainly due to resection of subcortical lesions near the pyramidal tracts.[3,8,15]

The fiber-tracking technique based on DT imaging shows the 3D macroscopic architecture of fiber tracts.[6,12,21,30,31] Recently, investigators have developed a new method for anatomofunctional mapping, using tractography-integrated functional neuronavigation combined with direct fiber electrical stimulation (MEP recording).[5,14,24] We have reported on the use of this method by using 3-tesla MR imaging.[26] To understand the clinical impact of this new technique on motor outcome during the resection of brain tumors located near the pyramidal tracts, we have directly compared the results of fiber tracking and subcortical electrical stimulation during intraoperative neuronavigation. Neurological evaluations of motor function were performed during the surgery and postoperatively.

Clinical Material and Methods

All procedures were approved by the ethics committee, and written informed consent was obtained from all patients.

Patient History

We examined 40 patients, 15 to 69 years of age, with

Abbreviations used in this paper: CT = computed tomography; DICOM = digital imaging and communications in medicine; DT = diffusion-tensor; MEP = motor evoked potential; MPRAGE = magnetization prepared rapid gradient echo; MR = magnetic resonance; ROI = region of interest.

tumors located close to the pyramidal tracts. These tumors included one pilocytic astrocytoma, 10 diffuse astrocytomas, 14 anaplastic astrocytomas, eight glioblastomas multiforme, two oligodendrogliomas, one ependymoma, and four cavernomas (Table 1). In all patients, the lesion margins were less than 2 cm from the pyramidal tracts identified by preoperative fiber tracking. Mild motor weakness was observed preoperatively in five patients.

TABLE 1

Summary of the clinical characteristics of 40 patients with brain tumors

Tumor Type & Location	No. of Patients
histological type	
pilocytic astrocytoma	1
diffuse astrocytoma	10
anaplastic astrocytoma	14
glioblastoma multiforme	8
oligodendroglioma	2
ependymoma	1
cavernoma	4
anatomical location (rt/lt)	
frontal lobe	4/16
temporal lobe	2/5
insular cortex	2/5
parietal lobe	2/2
brainstem	2

Diffusion-Tensor Data Acquisition and Processing for Fiber Tracking

Detailed methods used in fiber tracking have been described elsewhere by one of the authors.[25,26] A whole-body 3-tesla MR imager (Trio, Siemens) was used to perform preoperative DT imaging as well as anatomical T_1- and T_2-weighted volume imaging. The T_1-weighted volume data were obtained using a 3D MPRAGE sequence, and the T_2-weighted volume data were obtained using a 3D true fast imaging with steady-state precession sequence.

Fiber Tractography Data Processing for use in the Navigation System

Fiber tracking was performed using all pixels inside the brain (that is, with the brute force approach) and was begun in both the orthograde and retrograde directions, according to the direction of the principal eigenvector in each voxel. Results that penetrated the manually segmented ROIs based on the known anatomical distributions of tracts were assigned to those specific tracts. To reconstruct the pyramidal tract using tractography, two ROIs were segmented on axial non–diffusion weighted images: the first ROI at both cerebral peduncles, and the second ROI at both precentral gyri.[21,26,31]

In the process of converting tractography data into a DICOM-format data set, three steps were used. In the first step, tractography data were changed into a voxel data set. Using DtiStudio software version 2.02 (H. Jiang, S. Mori: Department of Radiology, Johns Hopkins University), an 8-bit voxel data set with binary contrast was created from the original tractography data with the same matrix size as non–diffusion weighted images. In this voxelized tractography data set, marked voxels (where fiber tracts showed penetration) showed the largest value, whereas other voxels displayed the smallest value.[19]

In the second step, tractographic images and non–diffusion weighted images were merged, using the same matrix size as that for MPRAGE images. The three orthogonal coordinates of each voxel on MPRAGE and non–diffusion weighted images were obtained from the DICOM header information. To calculate voxel values, trilinear interpolation was used. Merged images were generated from interpolated tractographic images and interpolated non–diffusion weighted images.

In the third step, merged images were converted into DICOM format according to the MPRAGE header information. Tractography studies in DICOM format with the same imaging matrices as MPRAGE studies were obtained.

Preparation in the Navigation System

The MPRAGE images, fast imaging with steady-state precession images, and DICOM-format tractography images were transferred to the navigation system (StealthStation TRIA plus with Cranial 4.0 software, Medtronic Sofamor-Danek; or Vector Vision Compact Navigation System with VV Cranial 7.5 software, BrainLab AG). We applied nonrigid image fusion to the images using ImMerge or iPlan 2.5 software, based on a mutual information algorithm. The day before the operation, we performed axial whole brain CT with a contiguous slice thickness of 1 mm by attaching six independent scalp point markers to the patient for anatomical registration. The CT image data set was also transferred to the navigation system. Computed tomography images, MPRAGE images, and DICOM-format tractography were registered automatically, and the anatomical registration points were verified to minimize navigation error. The differences in distortions between DT imaging and MPRAGE imaging were within a few millimeters according to our study using a phantom for the neuronavigation system, and therefore spatial accuracy of the single-shot echo planar sequence would be reliable. The potential for error during neuronavigation due to image distortions would be limited to a few millimeters. The accuracy of image registration was within 2 mm at navigation setup.

Intraoperative Electrical Stimulation

The bilateral abductor pollicis brevis, biceps, brachialis, deltoid, gastrocnemius, quadriceps femoris, and tibialis anterior muscles were selected for electromyographic recording by using neurological monitoring (Epoch XP, Axon Systems). General anesthesia was induced and maintained with intravenous infusion of propofol during the craniotomy. Muscle relaxants were administered only for intubation procedures and not during surgery. A peripheral nerve stimulator was used to confirm train-of-four muscle contractions. To identify the central sulcus, the highest N20 to P20 phase reversal of somatosensory evoked potentials was recorded using 4 × 5 subdural electrodes. For electrophysiologically monitoring the motor function of corticospinal tracts, the precentral gyrus was first stimulated to identify a positive control MEP as well as the intensity that was to be further used to stimulate the subcortical fiber. The intensity for cortical stimulation was increased by 1-mA increments, from 5 mA to a maximum of 15 mA. If afterdischarges

were induced, the test was repeated with the same current level intensity or at a current level 1 mA lower.

During the removal of tumors within 3 cm of the pyramidal tracts using intraoperative neuronavigation, subcortical electrical stimulations were carried out repetitively. Bipolar stimulation of five trains with monophasic square waves and a duration of 0.2 msec were applied with a frequency of 1 Hz. For language and sensory testing, a 50-Hz electrical current was delivered.[20] Language functions were assessed during spontaneous speech, naming, reading a paragraph, and were also based on reading comprehension.[20] Sensory function of both positive and negative symptoms was evaluated by the examiner.

We confirmed the points of stimulation by visualization on the neuronavigation system. In all patients, the minimum distances between the points of stimulation and the fiber tracking of the pyramidal tracts were measured with 3D MR imaging during intraoperative neuronavigation.

Surgical Procedures

All of the patients underwent tumor removal with the combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. After the administration of local anesthetic agent, motor function of the four extremities in 28 patients was continuously monitored using the muscle maneuver test[7] during removal of tumors near the pyramidal tracts. In these patients, language function was evaluated with the same testing procedures as those used for electrical stimulation, depending on the location of the tumor. Single-digit multiplication was performed by three patients in whom part of the tumor extended to the left parietal lobe. Resection of the lesions was ceased when a subcortical stimulation elicited an MEP response or language dysfunction. All elicited responses were recorded on video and later confirmed.

Results

Motor function was preserved postoperatively in all patients. In five patients with preoperative mild motor weakness in the upper or lower extremities, motor ability improved to full strength on the 2nd postoperative day (Table 2). Three resections were terminated due to the appearance of a disturbance in reading and naming ability caused by electrical stimulation.

Among 21 patients in whom MEPs were elicited, the distance between the estimated pyramidal tracts and the site of the positive MEPs was 1 cm or less in 18 patients (Fig. 1). Mild preoperative motor weakness in the upper extremities improved intraoperatively in two of four patients overall. Mild and transient motor weakness of the contralateral hand occurred when the first MEP was observed in the other two patients.

The distance between the estimated pyramidal tracts and the site of stimulation was 1 to 2 cm in 15 patients, and MEP recordings were negative in 12 of these patients. Two of these 15 patients suffered postoperative supplementary motor area syndrome,[10] which lasted for 2 weeks. In the remaining five patients, MEPs were never elicited by stimuli more than 2 cm from the estimated pyramidal tracts.

Discussion

This study showed the clinical impact of integrated functional neuronavigation and subcortical electrical stimulation for preserving motor function while attaining adequate tumor resection. Various methods, including positron emission tomography, functional MR imaging, magnetoencephalography, and electrical stimulation, have been shown to be effective for functional mapping and monitoring to preserve motor function at the cortical level. For better surgical outcomes, DT fiber tractography and/or subcortical electrical stimulation have been used to evaluate both the anatomical and functional condition of the pyramidal tracts. Several limitations to these approaches, however, have not been resolved.

Errors in track trajectories estimated by fiber tracking are

TABLE 2

*Relationships among distance, MEP response, and motor function in 40 patients with brain tumors**

Distance (cm)†	No. of Patients	MEP Recordings (no. of patients)	Preop Motor Weakness (no. of patients)‡	Intraop Change in Motor Function (no. of patients)§	Postop Motor Function Results (no. of patients)‖
0–1	20	positive (18)	present (3)		
			upper, Grade 4/5	improved to Grade 4+/5	improved to Grade 5/5
			upper, Grade 4/5	improved to Grade 4+/5	improved to Grade 5/5
			lower, Grade 4/5	no change	improved to Grade 5/5
			none (15)	no change (8), worsened (2)	no deficits (15)
		negative (2)	none (2)	no change (2)	no deficits (2)
1–2	15	positive (3)	none (3)	no change (3)	no deficits (3)
		negative (12)	present (1)		
			upper, Grade 4/5	no change	improved to Grade 5/5
			none (11)	no change (6)	SMA syndrome (2), no deficits (9)
2–3	5	positive (0)	NA	NA	NA
		negative (5)	present (1)		
			upper, Grade 4/5	no change	improved to Grade 5/5
			none (4)	no change (2)	no deficits (4)

* NA = not available; SMA = supplementary motor area.

† Distance between the electrically stimulated white matter and the pyramidal tracts on intraoperative neuronavigation.

‡ Motor function graded according to the Dejong scale.

§ Intraoperative change in motor function is the change in clinical symptoms during awake surgery (in 28 patients) caused by tumor resection, not by electrical stimulation.

‖ Postoperative motor function was compared with preoperative motor function on the 2nd day after the operation.



FIG. 1. Subcortical MEPs elicited intraoperatively in a 36-year-old woman with a right frontal diffuse astrocytoma. Her neurological examination was normal preoperatively. A: Intraoperative T_2-weighted MR images showing a hyperintense area (yellow area in *upper left panel*) close to the pyramidal tract identified by fiber tracking (green). During the removal of the tumor, subcortical stimulation elicited MEPs at the bottom of the tumor (intersection of *yellow lines*) 8 mm from the edge of the estimated pyramidal tract. No further removal was performed to avoid causing neurological deficits. B: Postoperative MR images demonstrating that the pyramidal tracts identified by fiber tracking (red) are preserved. C: A typical waveform of MEP response elicited from the left biceps muscle by subcortical stimulation during tumor removal.

known to be caused by low signal-to-noise ratios, the selection of the seed ROIs, the setting of thresholds for fractional anisotropy, the algorithm used in the procedure, or the effects of crossing fibers.[2,4,18] Intraoperative brain shift during surgery should also be considered.[28] In addition to the technical factors mentioned, other factors such as preoperative motor weakness and tumor-related edema can also affect the results of fiber tracking and MEP responses.[16] Additionally, MEP responses are affected by the condition of electrical stimulation;[13] the type of electrodes;[22] and errors in electrical stimulation due to current spread, electrical conductivity, and resistance.[3,11,27,29] These possible errors in the results of MEP recordings may cause postoperative motor deficits following resection of subcortical lesions near the pyramidal tract.[3,8]

Taking these limitations into consideration, complementary use of fiber tracking and subcortical MEPs in the present study offers clinical anatomical–functional information that aids in the preservation of pyramidal tracts. Combined use of these two methods in the present study has shown better surgical outcome in the preservation of motor function than outcomes repeated following MEP monitoring alone[3,8,15] or fiber tracking alone.[1,32] From the neurooncological point of view, subcortical electrical mapping has sig-

nificantly improved the survival rate of patients undergoing low-grade glioma resections.[8] We believe that combined functional neuronavigation and subcortical electrical stimulation during removal of nonmalignant gliomas will contribute to further improvement of the survival rate and maintenance of a high quality of life.

Because intraoperative MR imaging frequently cannot be performed during tumor resection, evaluation of the distance between the site of resection and the pyramidal tracts on intraoperative neuronavigation would be important for determining the optimal time to apply subcortical stimulation. During the removal of tumors located approximately 1 cm from the pyramidal tracts in the course of neuronavigation, repetitive subcortical electrical stimulation should be applied. The presence of subcortical MEPs during resection of a tumor is an important warning sign of the occurrence of permanent motor weakness, and therefore further resection after obtaining the first MEP response should be avoided.[15,16] Alternatively, lesions could be removed without injury to the pyramidal tracts if the estimated fibers were more than 2 cm away on intraoperative neuronavigation. To clarify the critical distance between the subcortex to be electrically stimulated and the estimated pyramidal tracts, further studies with DT image processing during the course of surgery with the use of intraoperative MR imaging are needed.[24] In addition to its use in subcortical mapping of the pyramidal tracts, MEP monitoring using cortical or transcranial electrical stimulation should also be considered as a way to preserve motor function.[17,23,32,33]

Conclusions

In 40 patients with brain tumors located near the pyramidal tracts, MEPs were elicited from the subcortex in 18 of 20 patients when the distance between the stimulated subcortex and the estimated pyramidal tracts on tractography-integrated intraoperative neuronavigation was within 1 cm. In the other 20 patients, with distances greater than 1 cm between the stimulated subcortex and the estimated pyramidal tracts, MEPs were elicited in only three patients. During removal of tumors located within 1 cm from the pyramidal tracts on functional neuronavigation, subcortical electrical stimulation should be applied to preserve motor function.

References

1. Beppu T, Inoue T, Kuzu Y, Ogasawara K, Ogawa A, Sasaki M: Utility of three-dimensional anisotropy contrast magnetic resonance axonography for determining condition of the pyramidal tract in glioblastoma patients with hemiparesis. **J Neurooncol 73:** 137–144, 2005
2. Berman JI, Berger MS, Mukherjee P, Henry RG: Diffusion-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with gliomas. **J Neurosurg 101:**66–72, 2004
3. Cedzich C, Taniguchi M, Schafer S, Schramm J: Somatosensory evoked potential phase reversal and direct motor cortex stimulation during surgery in and around the central region. **Neurosurgery 38:**962–970, 1996
4. Clark CA, Barrick TR, Murphy MM, Bell BA: White matter fiber tracking in patients with space-occupying lesions of the brain: a new technique for neurosurgical planning? **Neuroimage 20:** 1601–1608, 2003
5. Coenen VA, Krings T, Axer H, Weidemann J, Kranzlein H, Hans FJ, et al: Intraoperative three-dimensional visualization of the pyramidal tract in a neuronavigation system (PTV) reliably predicts true position of principal motor pathways. **Surg Neurol 60:** 381–390, 2003
6. Coenen VA, Krings T, Mayfrank L, Polin RS, Reinges MH, Thron A, et al: Three-dimensional visualization of the pyramidal tract in a neuronavigation system during brain tumor surgery: first experiences and technical note. **Neurosurgery 49:**86–93, 2001
7. Dejong RN: Case taking and the neurologic examination, in Barker AB (ed): **Clinical Neurology.** New York: Hoeber-Harper, 1955, Vol 1, pp 1–100
8. Duffau H: Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumor and brain plasticity. **Lancet Neurol 4:**476–486, 2005
9. Duffau H, Gatignol P, Mandonnet E, Peruzzi P, Tzourio-Mazoyer N, Capelle L: New insights into the anatomo-functional connectivity of the semantic system: a study using cortico-subcortical electrostimulations. **Brain 128:**797–810, 2005
10. Duffau H, Lopes M, Denvil D, Capelle L: Delayed onset of the supplementary motor area syndrome after surgical resection of the mesial frontal lobe: a time course study using intraoperative mapping in an awake patient. **Stereotact Funct Neurosurgery 76:** 74–82, 2001
11. Haglund MM, Ojemann GA, Blasdel GG: Optical imaging of bipolar cortical stimulation. **J Neurosurgery 78:**785–793, 1993
12. Hendler T, Pianka P, Sigal M, Kafri M, Ben-Bashat D, Constantini S, et al: Delineating gray and white matter involvement in brain lesions: three-dimensional alignment of functional magnetic resonance and diffusion-tensor imaging. **J Neurosurgery 99:** 1018–1027, 2003
13. Hern JE, Landgren S, Philips CG, Proter R: Selective excitation of corticofugal neurones by surface-anodal stimulation of the baboon's motor cortex. **J Physiol 161:**73–90, 1962
14. Kamada K, Todo T, Masutani Y, Aoki S, Ino K, Takano T, et al: Combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. **J Neurosurg 102:**664–672, 2005
15. Keles GE, Lundin DA, Lamborn KR, Chang EF, Ojemann G, Berger MS: Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. **J Neurosurg 100:** 369–375, 2004
16. Kinoshita M, Yamada K, Hashimoto N, Kato A, Izumoto S, Baba T, et al: Fiber-tracking does not accurately estimate size of fiber bundle in pathological condition: initial neurosurgical experience using neuronavigation and subcortical white matter stimulation. **Neuroimage 25:**424–429, 2005
17. Kombos T, Suess O, Ciklatekerlio O, Brock M: Monitoring of intraoperative motor evoked potentials to increase the safety of surgery in and around the motor cortex. **J Neurosurgery 95:** 608–614, 2001
18. Lin CP, Tseng WY, Cheng HC, Chen JH: Validation of diffusion tensor magnetic resonance axonal fiber imaging with registered manganese-enhanced optic tracts. **Neuroimage 14:**1035–1047, 2001
19. Masutani Y, Aoki S, Abe O, Hayashi N, Otomo K: MR diffusion tensor imaging: recent advance and new techniques for diffusion tensor visualization. **Eur J Radiol 46:**53–66, 2003
20. Mikuni N, Ohara S, Ikeda A, Hayashi N, Nishida N, Taki J, et al: Evidence for a wide distribution of negative motor areas in the perirolandic cortex. **Clin Neurophysiology 117:**33–40, 2006
21. Mori S, van Zijl PC: Fiber tracking: principles and strategies—a technical review. **NMR Biomed 15:**468–480, 2002
22. Nathan SS, Sinha SR, Gordon B, Lesser RP, Thakor NV: Determination of current density distributions generated by electrical stimulation of the human cerebral cortex. **Electroencephalogr Clin Neurophysiology 86:**183–192, 1993

23. Neuloh G, Pechstein U, Cedzich C, Schramm J: Motor evoked potential monitoring with supratentorial surgery. **Neurosurgery 54:**1061–1072, 2004
24. Nimsky C, Grummich P, Sorensen AG, Fahlbusch R, Ganslandt O: Visualization of the pyramidal tract in glioma surgery by integration diffusion tensor imaging in functional neuronavigation. **Zentralbl Neurochir 66:**133–141, 2005
25. Okada T, Miki Y, Fushimi Y, Hanakawa T, Kanagaki M, Yamamoto A, et al: Diffusion-tensor fiber tractography: intraindividual comparison of 3.0-t and 1.5-t MR imaging. **Radiology 238:** 668–678, 2006
26. Okada T, Mikuni N, Miki, Y, Kikuta K, Urayama S, Hanakawa T, et al: Corticospinal tract localization: integration of diffusion-tensor tractography at 3-t MR imaging with intraoperative white matter stimulation mapping—preliminary results. **Radiology 240:** 849–857, 2006
27. Pouratian N, Cannestra AF, Bookheimer SY, Martin NA, Toga AW: Variability of intraoperative electrocortical stimulation mapping parameters across and within individuals. **J Neurosurg 101:** 458–466, 2004
28. Reinges MH, Nguyen HH, Krings T, Hutter BO, Rohde V, Gilsbach JM: Course of brain shift during microsurgical resection of supratentorial cerebral lesions: limits of conventional neuronavigation. **Acta Neurochir (Wien) 146:**369–377, 2004
29. Taniguchi M, Cedzich C, Schramm J: Modification of cortical stimulation for motor evoked potentials under general anesthesia: technical description. **Neurosurgery 32:**219–226, 1993
30. Witwer BP, Moftakhar R, Hasan KM, Deshmukh P, Haughton V, Field A, et al: Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. **J Neurosurgery 97:**568–575, 2002
31. Yamada K, Kizu O, Mori S, Ito H, Nakamura H, Yuen S, et al: Brain fiber tracking with clinically feasible diffusion-tensor MR imaging: initial experience. **Radiology 227:**295–301, 2003
32. Yu CS, Li KC, Xuan Y, Ji XM, Qin W: Diffusion tensor tractography in patients with cerebral tumors: a helpful technique for neurosurgical planning and postoperative assessment. **Eur J Radiol 56:**197–204, 2005
33. Zhou HH, Kelly PJ: Transcranial electrical motor evoked potential monitoring for brain tumor resection. **Neurosurgery 48:** 1075–1081, 2001

Manuscript submitted June 2, 2006.
Accepted November 7, 2006.

Address reprint requests to: Nobuhiro Mikuni, M.D., Ph.D., Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 kawahara-cho, Shogoin, Sakyo-ku, Kyoto 6068507, Japan. email: mikunin@kuhp.kyoto-u.ac.jp.

脳腫瘍の診断

渋井壮一郎*

はじめに

「頭痛があれば脳腫瘍を疑う」というのは間違いではない．しかしながら，頭痛を経験したことのない人はほとんどいないといえるが，脳腫瘍の発生頻度は10万人に12～14人程度であり，およそ8,000人に1人というわずかな人数である．確率としてはかなり低いが，脳腫瘍の診断はまず「その存在を疑う」ことから始まる．

症　状

脳腫瘍の症状は，頭蓋内圧亢進症状と巣症状とに分けられる．前者は頭蓋骨という閉鎖空間に異物があることで起こる症状である．良性腫瘍のようにゆっくりと大きくなる腫瘍の場合は，脳自体の変形や脳脊髄液腔の縮小などにより，頭蓋内圧は上がらず，その結果，直径が5 cmを越えるような大きな腫瘍でも頭痛や嘔気を生じないこともある．一方，悪性腫瘍では増大する速度が速く，さらに周囲に広範な脳浮腫を伴うことが多いため，小さな腫瘍でも頭痛で発症することも珍しくない．これに対し，巣症状は腫瘍の占める部位による症状である．脳は，機能局在がはっきりしており，前頭葉と頭頂葉の境界をなす中心溝のすぐ前の障害では反対側の運動麻痺，中心溝の後の障害では反対側の感覚障害，後頭葉では，反対側の視野障害(同名半盲)，優位半球(多くは左側)前頭葉では運動性失語(理解はできるが発語が困難)，側頭葉では感覚性失語(言語理解不能)を来たす．脳腫瘍ではこれらの症状が数週間あるいは数ヵ月かかって徐々に進行するのが特徴であるが，痙攣や腫瘍内出血を伴い，急性発症する場合もあるため注意を要する．

疫　学

原発性脳腫瘍の発生原因は不明である．神経線維腫症，ヒッペル・リンドウ病，結節性硬化症など遺伝的素因がわかっているものもあるが，大半の原発性脳腫瘍については，環境的素因を含め，因果関係が証明されているものはない．脳腫瘍全国統計による脳腫瘍の組織別頻度を表1に示す．最も多いのが神経膠腫(グリオーマ)，次に髄膜腫，下垂体腺腫，神経鞘腫，頭蓋咽頭腫などの良性腫瘍が続く．近年の特徴として，髄膜腫や下垂体腫瘍が増加の傾向にあり，グリーマの比率は減少していること，中枢神経原発の悪性リンパ腫が急激に増加していることなどがあげられる．

画像診断

脳腫瘍の確定診断を得るためには，摘出した腫瘍に対する組織診断である．通常のHE(ヘマトキシリン・エオジン)染色で大半の診断は可能であるが，免疫組織化学的染色を追加することで，細分類も可能になる．さらに最近では遺伝子情報も診断に応用されるようになっている．しかしながら，臨床の場では，治療方針を立てる意味でも術前の診断が必要であり，実際にはかなりの腫瘍が画像から組織診断を推測することが可能である．

*Soichiro SHIBUI：国立がんセンター中央病院脳神経外科医長

▶表1　脳腫瘍全国統計による原発性脳腫瘍の頻度(1991－1996年登録症例)

	全例	年齢(歳)		
		<15	15-69	>70
神経膠腫	27.3%	57.7%	24.3%	26.9%
髄膜腫	26.2	2.0	26.2	42.3
下垂体腺腫	15.2	1.9	17.2	10.1
神経鞘腫	10.4	1.1	11.8	7.1
頭蓋咽頭腫	3.5	9.0	3.3	1.6
悪性リンパ腫	2.9	0.4	2.6	6.7
血管芽腫	1.7	0.4	2.0	1.0
類表皮嚢胞・類皮嚢胞	1.6	1.6	1.7	0.5
胚細胞腫	2.8	15.4	2.0	0.0
その他	8.4	10.5	8.9	3.8
合　計	100.0 (*n*=51,818)	100.0 (*n*=4,070)	100.0 (*n*=41,653)	100.0 (*n*=6,095)

(脳腫瘍全国統計委員会：Neuro Med Chir 43(suppl), 2003)



▲図1　髄膜腫のMRI T1強調画像(ガドリニウム造影)

髄膜腫(図1)

髄膜(硬膜，クモ膜，軟膜)より発生するため，通常は脳表に見られる．良性腫瘍であり，MRIでは境界鮮明で，造影剤(ガドリニウム)にて強く造影される．男女比1：2.7で女性に多い．好発部位として，傍矢状部，大脳鎌，大脳半球円蓋部，蝶形骨縁，嗅窩，鞍結節部などがある．全摘により治癒するが，部位により摘出が困難な場合はガンマナイフ治療も行われる．

下垂体腺腫(図2)

脳下垂体より発生する良性腫瘍で，ホルモン非分泌性腫瘍とホルモン分泌性腫瘍(プロラクチン，成長ホルモン，副腎皮質刺激ホルモン，甲状腺刺激ホルモン，卵胞ホルモン，黄体ホルモン)に分けられる．前者はホルモンの分泌障害，後者は分泌過多による症状を呈する．脳下垂体の直上は視交叉部にあたり，腫瘍が上方に進展するに従い，視力・視野障害を来たす．典型的には両耳側半盲(左右とも外側半分の視野欠損)を呈する．治療として，上歯肉を切



◀図2　下垂体腺腫のMRI



◀図3　聴神経腫瘍(神経鞘腫)のMRI

開し経蝶形骨的な手術が行われることが多いが，最近は内視鏡を用いた経鼻的手術も行われている．残存腫瘍に対しては放射線治療も行われる．プロラクチン産生性の腫瘍にはブロモクリプチンやカベルゴリンが著効する．

■ 神経鞘腫(図3)

頭蓋内神経鞘腫の大半は，小脳橋角部に発生する聴神経腫瘍である．ガドリニウムにて造影される境界鮮明な腫瘍で，嚢胞を形成することもある．聴神経を構成する前庭神経側から発生することが多いので，かなり大きな腫瘍でも聴力が残っていることがある．その他，三叉神経，頸静脈孔(舌咽・迷走・副神経)，顔面神経にも見られる．治療としては手術が主体であるが，直径3 cm以下の腫瘍に対してはガンマナイフも用いられている．治療に伴う合併症として，聴神経腫瘍では顔面神経麻痺，頸静脈孔腫瘍では，嗄声・嚥下障害などが問題になる．特殊型として神経線維腫症に伴う両側聴神経腫瘍がある．

■ 神経膠腫(グリオーマ)

脳実質内のグリア細胞から発生する腫瘍で，星細胞腫が80％程度を占める．星細胞腫は悪性度によりgrade 1から4までに分類されており，grade 1は毛様細胞性星細胞腫，grade 2はびまん性星細胞腫，grade 3は退形成性星細胞腫，grade 4は膠芽腫と呼ばれ，grade 1以外は悪性腫瘍の範疇に入る．Grade 1は小児の小脳に発生することが多いが，その他は成人が主体である．Grade 2はMRIのT1強調画像では黒く，T2およびFLAIR法にて白く描出され，造影剤による増強が少ない(図4)．これに対し，



▶図4　びまん性星細胞腫
左：造影 MRI T1 強調画像，右：T2 強調画像



▶図5　膠芽腫の MRI

grade 3 および 4 は，造影剤に増強されることが多い(図5)．Grade 3, 4 に対しては，手術，放射線，化学療法を組み合わせた治療が行われているが，前者の 5 年生存率は 23%，後者は 7%程度である．最も悪性度の高い膠芽腫でも，手術的に摘出できたものの生存率が高いため，可能な限り摘出を行い，腫瘍の周囲の脳浮腫を含めた領域に 50～60 Gy の放射線照射が行われる．この際，通常は化学療法剤を併用する．

転移性脳腫瘍(図6)

転移性脳腫瘍は，がん患者の 20～40%にみられるといわれ，原発性脳腫瘍の 10 倍程度発生するとされている．原発がんとして最も多いのが肺がん(52%)，続いて乳がん(9%)，大腸がん(9%)，腎がん(5%)，胃がん(5%)があげられる．半数以上は多発である．転移性脳腫瘍に対する治療は一様でない．原発巣は比較的よくコントロールされており，6 ヵ月程度の生命予後が期待され，直径 3 cm を越える大きな単発性腫瘍に対しては積極的に手術を行い，術後放射線治療を行う．小さな腫瘍，多発性腫瘍については放射線治療が優先される．通常の放射線以外に，最近ではガンマナイフやリニアックによる定位放射線治療が取り入れられている．転移性脳腫瘍は強い脳浮腫により，比較的急激に神経症状が進行するが，あくまで全身疾患の一部であることを念頭に置き，治療にあたる必要がある．



▲図6 肺原発多発性脳転移のMRI

おわりに

最近は，国内のどの医療機関にもCTやMRIの設備があり，非侵襲性の検査ができるようになった．その結果，症状の軽微なうちに腫瘍が発見されることが多くなっている．脳腫瘍の診断の第一歩は「疑う」ことであり，実際にうつ病とか加齢に伴う記銘力障害として見過ごされている場合も少なくないので注意を要する．

●文　献

1) 脳腫瘍全国統計委員会：Brain Tumor Registry of Japan. Neurol Med Chir **43**(suppl), 2003

脳腫瘍の放射線治療・化学療法

渋井壮一郎*

はじめに

悪性脳腫瘍は浸潤性に発育するため，手術による摘出のみでは通常再発を来たす．そこで，術後の放射線治療が行われるが，その効果を高めるため化学療法が併用されることが多い．とくに悪性神経膠腫（グリオーマ）では，ニトロソウレア系の抗がん剤との併用が多く，化学放射線治療としてその効果が評価される．

標準治療

標準治療とは，科学的証拠（エビデンス）に裏付けされ，現時点で最も治療効果の期待できる治療と定義される．本来，どの施設においても標準治療がなされるべきであるが，悪性グリオーマについては，絶対的効果の期待できる薬剤がなく，各施設でまちまちな治療が行われているのが現状である．標準治療を構築していくためには，一定の基準に従った臨床試験が必要である．とくに大規模なランダム化比較試験はエビデンスのレベルが高く，信頼性の高い結果を導き出すことができる（表1）．ランダム化比較試験は第Ⅲ相試験とも言われ，従来の標準治療に対し，有効性の期待できる新治療の効果を比較するものである．通常は，第1次の評価項目（エンドポイント）として生存率あるいは生存期間が選ばれ，両者を統計的に比較する．第2次の評価項目としては奏効率（CTやMRIでの縮小率）や有害事象発生率などが選ばれる．両者の比較の結果，統計的に優っているものが次の標準治療として残ることになる．ただし，エンドポイントのわずかな差から有意差を証明するには，多くの症例数が必要となり，多施設共同の臨床試験が必須となる．

▼表1　エビデンスレベルと推奨グレード（米国臨床腫瘍学会：ASCO）

エビデンスレベル
Ⅰ．多数の良質比較試験のメタアナリシス，大規模無作為化比較試験
Ⅱ．1つ以上の良質の実験的研究，小規模無作為化比較試験
Ⅲ．良質の準実験的研究（非無作為化，コホートなど）
Ⅳ．よいデザインの非実験的比較試験，症例研究
Ⅴ．症例報告
推　奨　度
A．Level Ⅰ，または複数のLevel Ⅱ，Ⅲ，Ⅳの結果が一致（強く勧められる）
B．Level Ⅱ，Ⅲ，Ⅳの結果が一致（行うよう勧められる）
C．Level Ⅱ，Ⅲ，Ⅳの結果が不一致（勧める根拠がない）
D．Evidenceなし（行わないよう勧められる）

悪性グリオーマ治療のエビデンス

欧米では，1970年代後半より，大規模な臨床試験が実施されており，悪性グリオーマの治療に関するエビデンスが確立してきたといえる．その結果，放射線単独照射において，45 Gyより60 Gyまで徐々に照射量を上げるに従い，平均生存期間が統計的に有意に延長し，さらに，ニトロソウレア系抗がん剤のBCNU（カルムスチン）を併用するこ

*Soichiro SHIBUI：国立がんセンター中央病院脳神経外科医長



▲図 1　星細胞腫 grade 3-4 に対する JCOG 臨床試験のシェーマ

とで，いっそうその効果が高まることが証明された．この試験を含め 12 のランダム化臨床試験の結果をまとめた報告でも，ニトロソウレア系抗がん剤を併用することで，放射線単独治療に比べ，1 年生存で 6%，2 年生存で 5%の上昇が示され，放射線＋ニトロソウレアが標準治療とされるようになった．化学療法剤としては BCNU 以来，いろいろな薬剤が用いられてきたが，それ以上の効果を示すものがなかった．国内では，放射線単独治療と放射線＋ACNU（ニムスチン）の効果を比較した高倉らの報告が唯一のエビデンスといわれるものであるが，集められた症例数の問題もあり，奏効率において後者が優ったものの，生存率に有意な差が認められなかった．その後，国内での大規模な臨床試験結果の発表はないまま今日に至っているが，現在，日本臨床腫瘍研究グループ（JCOG）の脳腫瘍グループが，国内での標準治療を確立することを目的として，放射線＋ACNU と放射線＋ACNU＋プロカルバジンの第Ⅱ/Ⅲ相試験を行っている．これは，ACNU に対する耐性機構のひとつである O6-methylguanine DNA-methyltransferase（MGMT）という酵素をプロカルバジンが低下させるということを利用し，これを ACNU 投与より 1 週間前から開始する方法と従来の ACNU 単独による化学放射線治療を比較するものである（図 1）．

テモゾロミドによる治療

2005 年に，ヨーロッパとカナダの共同研究グループ（EORTC/NCIC）から今後の悪性グリオーマ治療の方向付けをする報告がなされた．これは，膠芽腫に対し，経口抗がん剤テモゾロミドを併用した放射線治療と放射線単独治療との効果を比較したランダム化試験であるが，おのおの 280 例を超える登録数による生存期間中央値は，放射線単独が 12.1 ヵ月であったのに対し，テモゾロミド併用群では 14.6 ヵ月となり，2 年生存率も前者が 10.4%，後者が 26.5%と，膠芽腫に対する治療としては，初めて放射線単独を有意に上回ったというものである（図 2）．この報告により，欧米での悪性グリオーマに対する標準治療はテモゾロミドとなり，次の段階として，その投与方法あるいは，他の薬剤との組み合わせの工夫が始まっている．国内でも 2006（平成 18）年 9 月に保険診療での使用が可能になり，いっせいに使われるようになった．一般的な使用方法は，腫瘍摘出後，放射線治療と同時に 1 日 1 回空腹時に 75 mg/m² のテモゾロミドを開始し，6 週間の放射線治療期間中服用を継続する．放射線治療終了後は，4 週間後に 1 日 150 mg/m² を 5 日間服用し 23 日間休薬する．その後は，有害事象の程度に応じた増量基準，減量基準に従い，28 日ごとに 5 日間服用する治療を 6 回繰り返す（図 3）．テモゾロミドは，経口投与によって速やかに吸収され，生理的 pH で加水分解されて抗腫瘍効果を発揮するため，人種差もほとんどないといわれている薬剤で，しかも脳脊髄液への移行も優れていると報告されている．さらに，化学療法剤の使用においての重要な副作用である骨髄抑制が軽度であり，治療が予定通りに実施できる利点もある．もちろん，副作用が全くないわけではなく，骨髄抑制とくにリンパ球減少が半数例に認められ，それも誘因のひとつと考えられるカリニ肺炎例が報告されており，その予防対策が必要である．

放射線治療

悪性グリオーマに対する放射線治療は，通常，化学療法剤との併用で行われる．かつての欧米の臨床試験では全脳



◀図2　EORTC-NCIC による膠芽腫に対するテモゾロミド＋放射線治療と放射線単独治療との比較試験結果



▲図3　テモゾロミドによる悪性グリオーマ治療のスケジュール

照射が行われていたが，再発の大半が腫瘍の周辺から起こるという事実から，前述の EORTC や JCOG の試験をはじめ，最近では局所照射が行われることが多い．治療計画は CT による 3 次元計画が原則であり，腫瘍本体を囲むように数 cm の幅をもたせて 60 Gy，さらにその外側の脳浮腫の部分には 40～50 Gy の照射が行われる．

転移性脳腫瘍の治療

転移性脳腫瘍に対して一定の化学療法は行われていない．原発病巣に対する化学療法が行われている場合は，それらが優先されるが，使用されている薬剤が必ずしも脳転移病巣に有効といえず，また血液脳幹門を通過しない薬剤であることもあるため，むしろ無効であることが多い．転移性脳腫瘍には放射線治療が有効であり，とくに直径 3 cm 以下の病巣にはガンマナイフなどの定位放射線照射が行われる．しかしながら，直径 3 cm を越える病巣では，定位照射により放射線壊死が出現する可能性が高く，手術が優先される．いくつかの臨床試験から確認されていることは，(1)直径 3 cm 以上の単発性腫瘍は放射線単独よりも手術＋放射線治療の予後がよいこと，(2)手術不能の単発腫瘍では，全脳照射単独より定位照射を追加したほうが予後がよいこと，(3)定位照射単独とそれに全脳照射を加えたものでは生存期間に差はないが，併用した群で，脳内の他の部分への再発が少ないこと，などである．全脳照射に伴う高次脳機能障害を予防する目的で，JCOG 脳腫瘍グループでは，多発性脳転移に対して手術後に，残存腫瘍に対する定位照射だけで治療をする方法と手術直後に全脳照射をする方法との比較試験を行っている(図4)．現時点では，3



▲図 4　転移性脳腫瘍に対する JCOG 臨床試験のシェーマ



▲図 5　転移性脳腫瘍に対する治療方針

cm 以上の腫瘍に対しては手術＋全脳照射を行い，それ以下の小さな腫瘍は，4～5 個くらいまでは定位照射を優先することが多い．現時点でのわれわれの治療方針を図 5 に示す．

おわりに

現在なお悪性脳腫瘍の予後はきわめて悪く，脳腫瘍全国統計による 5 年生存は膠芽腫では 7%，転移性脳腫瘍では 11%程度である．最近の手術，放射線，化学療法の進歩により，これら数字は向上する傾向はみられるものの，まだまだ十分とは言えない．画期的な治療法というのはたやすく生まれるものではなく，今，われわれにできることは一つひとつのエビデンスを積み重ねて，わずかでも良好な結果を期待できる治療法を実施していくことであると言える．昨今，国内においても，臨床試験の重要性が浸透し，JCOG をはじめとする多施設共同試験の基盤ができつつある．これらのグループの活動を通じて，悪性脳腫瘍治療のエビデンスが確立していくことが望まれる．

脳神経外科学

悪性脳腫瘍に対する新しい治療

Current advances in treatment for malignant brain tumors

悪性脳腫瘍の代表ともいえる悪性神経膠腫(グリオーマ)は，いまなお治療困難な疾患のひとつであり，治療のスタンダードも確立していない．1970年代から欧米では第Ⅲ相試験を含む臨床試験が実施され，その結果，予後を改善する因子として手術による摘出，放射線治療などがあげられてきた．化学療法については有意に予後の改善につながる薬剤はなく，BCNU(carmustine)などのnitrosurea系薬剤が，そのなかでも生存期間延長の傾向があり，20年来補助療法の薬剤として用いられてきた．2002年に発表されたメタアナリシスでは，悪性神経膠腫に対しnitrosourea系抗癌剤を併用した放射線治療群と放射線単独療法群の比較を，過去に発表された12の無作為化試験に登録された3,004例の症例について行った[1]．その結果，抗癌剤併用群の1年生存率が46%，放射線単独群が40%であり，有意に前者の生存率が勝っているという結果であり，nitrosourea併用の有効性が証明された．

日本の現状

一方，国内で確立されたエビデンスはほとんどなく，前述のメタアナリシスに加えられた論文もTakakuraらの1編のみであった．これは，国内で開発されたnitrosourea系抗癌剤であるACNU(nimustine hydrochloride)を併用した放射線治療群と放射線単独群の効果を比較した第Ⅲ相比較試験で，その結果，生存率では両者の差は認められなかったが，奏効率で前者が勝っているというものであり，これらの結果を踏まえ，国内ではACNU＋放射線治療が悪性神経膠腫治療のスタンダードとして用いられるようになった[2]．しかし，その効果は不十分であり，実際には各脳神経外科施設が独自の治療を行ってきたというのが実情である．

国内でのスタンダード確立のために，日本臨床腫瘍研究グループ(JCOG)内の脳腫瘍グループが第Ⅱ/Ⅲ相試験を実施している．これは術後の化学放射線治療としてACNU併用治療とprocarbazineおよびACNUを併用する治療を比較するものである．後者はprocarbazineをACNUに先行して投与し，ACNUに対する薬剤耐性を発揮するO^6-methylguanine DNA-methyltrasferase(MGMT)という酵素を阻害して，その効果を高めようという治療法である[3]．現在，第Ⅱ相段階が終了し，その有効性，安全性について検討中である．

Temozolomide(TMZ)併用放射線治療

2005年，European Organisation for Research and Treatment of Cancer(EORTC)から悪性神経膠腫の治療について画期的な報告がなされた．これは悪性神経膠腫のなかでもっとも悪性度の高い膠芽腫を対象とし，手術後にtemozolomide(TMZ)併用放射線治療を行い，さらに6コースの同剤による化学療法を行う群と放射線単独群とを比較した第Ⅲ相試験であり，両群とも280例を超える登録がなされ



放射線単独	286	240	144	59	23	2	0
放射線+TMZ併用	287	246	174	109	57	27	4

図1 膠芽腫に対する放射線単独照射と放射線＋Temozolomide(TMZ)の比較試験結果[4]

生存期間中央値は前者が12.1カ月に対し，後者は14.6カ月で，有意に生存期間の延長がみられた．

た[4]．その結果，併用群の生存期間中央値が14.6カ月，放射線単独群が12.1カ月であり，有意に前者の生存期間の延長がみられた．2年生存率も前者が26.5%，後者が10.4%であり，膠芽腫を対象とした臨床試験ではじめて有意な差をもって，放射線単独治療に対し，より有効な治療法として証明された(図1)．TMZは経口投与で髄液移行もよく，他の抗癌剤と比べ骨髄抑制も軽微であり，欧米ではすでに標準治療薬として用いられている．これらの試験結果を受け，国内でも第Ⅱ相試験が行われ，2006年9月保険治療薬として認可された．

治療法は，放射線治療開始時より6週間，75 mg/m^{2}を連日服用し，放射線終了後は28日ごとに最初の5日間に150 mg/m^2，減量基準に該当しなければ，2回目より200 mg/m^{2}を6コース服用するというものである．国内でも認可後6カ月で2,000例あまりに使用されているといわれ，有効例も数多く報告されている．有害事象として嘔気，嘔吐，便秘などがめだつほか，リンパ球減少との関連性も考えられるニューモシスチス肺炎(カリニ肺炎)による死亡が3例報告されており，ST(sulfamethoxazole/trimethoprim)合剤の使用が推奨されている．

おわりに

国内でも今後，TMZが悪性神経膠腫に対する標準治療薬として使用されると考えられるが，本剤の膠芽腫に対する効果も平均生存がたかだか14カ月であり，まだまだ十分なものとはいえない．とくに前述のMGMTの発現がみられる腫瘍については発現のない腫瘍に比べ，その効果が半減する(生存期間中央値12.7カ月 vs. 21.7カ月)といわれ，併用薬の工夫などが必要である．

TMZの出現により，30年来変化のなかった悪性神経膠腫の治療成績も若干向上することが期待できる．しかし，その治療成績はまだまだ満足できるものではなく，今後さらなる治療薬・治療法の開発が望まれる．

1) Stewart, L. A. and Meta-analysis Group：Chemotherapy in adult high-grade glioma：a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet*, **359**：1011-1018, 2002.
2) Takakura, K. et al.：Effects of ACNU and radiotherapy on malignant glioma. *J. Neurosurg.*, **64**：53-57, 1986.
3) Shibui, S. and Japan Clinical Oncology Group-Brain Tumor Study Group：Randomized controlled trial on malignant brain tumors—activities of the Japan Clinical Oncology Group-Brain Tumor Study Group. *Neurol. Med. Chir.* (*Tokyo*), **44**：220-221, 2004.
4) Stupp, R. et al.：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.*, **352**：987-996, 2005.

渋井壮一郎／Soichiro SHIBUI
国立がんセンター中央病院第二領域外来部脳神経科